Dabigatran Etexilate is To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation.
*The following content is generated by AI and is for reference only.
Overview
Dabigatran Etexilate is a prodrug of dabigatran, serving as a direct thrombin inhibitor. Its core synthesis involves esterification to enhance oral bioavailability. The molecular formula is C22H31N5O7 with CAS No. 269048-60-2.
Application
- Pharmaceutical manufacturing for anticoagulant tablets.
- Prevention of stroke in patients with non-valvular atrial fibrillation.
- Treatment and prevention of deep vein thrombosis post-surgery.
Precautions
Contraindicated in severe renal impairment and active bleeding. Store in cool, dry conditions below 25°C. Handle raw materials with PPE to avoid inhalation risks.